Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine.

Background: mutations are associated with an adverse prognosis in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). However, the integrated genetic, epigenetic, and immunologic landscape of -mutated AML/HR-MDS is not well defined.

Objectives: To define the genetic, epigenetic, and immunologic landscape of mutant and wild-type AML and HR-MDS patients.